FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034893607> ?p ?o ?g. }

• W2034893607 endingPage "940" @default.
• W2034893607 startingPage "934" @default.
• W2034893607 abstract "Objective To assess the efficacy and toxicity of local radiotherapy in achieving local control in patients with stage 4 or high-risk stage 3 neuroblastoma treated with induction chemotherapy and tandem stem cell transplants. Methods Fifty-two children with stage 4 or high-risk stage 3 neuroblastoma were treated on a standardized protocol that included five cycles of induction chemotherapy, surgical resection of the primary tumor when feasible, local radiotherapy, and then consolidation with tandem myeloablative cycles with autologous peripheral blood stem cell rescue. Local radiotherapy (10.5–18 Gy) was administered to patients with gross or microscopic residual disease prior to the myeloablative cycles. Thirty-seven patients received local radiotherapy to the primary tumor or primary tumor bed. Two patients with unknown primaries each received radiotherapy to single, unresectable, bulky metastatic sites. The second of the myeloablative regimens included 12 Gy of total body irradiation. Results Of the 52 consecutively treated patients analyzed, 44 underwent both transplants, 6 underwent a single transplant, and 2 progressed during induction. Local radiotherapy did not prolong recovery of hematopoiesis following transplants, did not increase peritransplant morbidity, and did not prolong the hospital stay compared with patients who had not received local radiotherapy. Local control was excellent. Of 11 patients with disease recurrence after completion of therapy, 9 failed in bony metastatic sites 3 to 21 months after the completion of therapy, 1 recurred 67 months following therapy in the previously bulky metastatic site that had been irradiated, and 1 had local recurrence concurrent with distant progression 15 months following the second transplant. The three-year event-free survival was 63%, with a median follow-up of 29.5 months. The actuarial probability of local control was 97%. Conclusions The use of induction chemotherapy, aggressive multimodality therapy for the primary tumor, followed by tandem myeloablative cycles with stem cell transplant in patients with stage 4 or high risk stage 3 neuroblastoma has resulted in acceptable toxicity, a very low local recurrence risk, and an improvement in survival." @default.
• W2034893607 created "2016-06-24" @default.
• W2034893607 creator A5011956202 @default.
• W2034893607 creator A5013532193 @default.
• W2034893607 creator A5016016418 @default.
• W2034893607 creator A5021120123 @default.
• W2034893607 creator A5021488317 @default.
• W2034893607 creator A5064025296 @default.
• W2034893607 creator A5070239163 @default.
• W2034893607 creator A5071816294 @default.
• W2034893607 creator A5089684523 @default.
• W2034893607 date "2003-12-01" @default.
• W2034893607 modified "2023-10-16" @default.
• W2034893607 title "Primary Tumor Control in Patients With Stage 3/4 Unfavorable Neuroblastoma Treated With Tandem Double Autologous Stem Cell Transplants" @default.
• W2034893607 cites W1535107443 @default.
• W2034893607 cites W1855252512 @default.
• W2034893607 cites W1910480474 @default.
• W2034893607 cites W1940650862 @default.
• W2034893607 cites W2081455238 @default.
• W2034893607 cites W2088231917 @default.
• W2034893607 cites W2130516503 @default.
• W2034893607 cites W2132322911 @default.
• W2034893607 cites W2157272402 @default.
• W2034893607 cites W2157341748 @default.
• W2034893607 cites W2262641481 @default.
• W2034893607 cites W2263175166 @default.
• W2034893607 cites W2267436557 @default.
• W2034893607 cites W2327522594 @default.
• W2034893607 cites W2330923897 @default.
• W2034893607 cites W4293241248 @default.
• W2034893607 doi "https://doi.org/10.1097/00043426-200312000-00005" @default.
• W2034893607 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14663275" @default.
• W2034893607 hasPublicationYear "2003" @default.
• W2034893607 type Work @default.
• W2034893607 sameAs 2034893607 @default.
• W2034893607 citedByCount "41" @default.
• W2034893607 countsByYear W20348936072012 @default.
• W2034893607 countsByYear W20348936072013 @default.
• W2034893607 countsByYear W20348936072014 @default.
• W2034893607 countsByYear W20348936072015 @default.
• W2034893607 countsByYear W20348936072016 @default.
• W2034893607 countsByYear W20348936072017 @default.
• W2034893607 countsByYear W20348936072018 @default.
• W2034893607 countsByYear W20348936072019 @default.
• W2034893607 countsByYear W20348936072022 @default.
• W2034893607 crossrefType "journal-article" @default.
• W2034893607 hasAuthorship W2034893607A5011956202 @default.
• W2034893607 hasAuthorship W2034893607A5013532193 @default.
• W2034893607 hasAuthorship W2034893607A5016016418 @default.
• W2034893607 hasAuthorship W2034893607A5021120123 @default.
• W2034893607 hasAuthorship W2034893607A5021488317 @default.
• W2034893607 hasAuthorship W2034893607A5064025296 @default.
• W2034893607 hasAuthorship W2034893607A5070239163 @default.
• W2034893607 hasAuthorship W2034893607A5071816294 @default.
• W2034893607 hasAuthorship W2034893607A5089684523 @default.
• W2034893607 hasConcept C121608353 @default.
• W2034893607 hasConcept C126322002 @default.
• W2034893607 hasConcept C141071460 @default.
• W2034893607 hasConcept C143998085 @default.
• W2034893607 hasConcept C146357865 @default.
• W2034893607 hasConcept C151730666 @default.
• W2034893607 hasConcept C2776611710 @default.
• W2034893607 hasConcept C2776694085 @default.
• W2034893607 hasConcept C2776715637 @default.
• W2034893607 hasConcept C2779013556 @default.
• W2034893607 hasConcept C2780283643 @default.
• W2034893607 hasConcept C509974204 @default.
• W2034893607 hasConcept C54355233 @default.
• W2034893607 hasConcept C71924100 @default.
• W2034893607 hasConcept C81885089 @default.
• W2034893607 hasConcept C86803240 @default.
• W2034893607 hasConceptScore W2034893607C121608353 @default.
• W2034893607 hasConceptScore W2034893607C126322002 @default.
• W2034893607 hasConceptScore W2034893607C141071460 @default.
• W2034893607 hasConceptScore W2034893607C143998085 @default.
• W2034893607 hasConceptScore W2034893607C146357865 @default.
• W2034893607 hasConceptScore W2034893607C151730666 @default.
• W2034893607 hasConceptScore W2034893607C2776611710 @default.
• W2034893607 hasConceptScore W2034893607C2776694085 @default.
• W2034893607 hasConceptScore W2034893607C2776715637 @default.
• W2034893607 hasConceptScore W2034893607C2779013556 @default.
• W2034893607 hasConceptScore W2034893607C2780283643 @default.
• W2034893607 hasConceptScore W2034893607C509974204 @default.
• W2034893607 hasConceptScore W2034893607C54355233 @default.
• W2034893607 hasConceptScore W2034893607C71924100 @default.
• W2034893607 hasConceptScore W2034893607C81885089 @default.
• W2034893607 hasConceptScore W2034893607C86803240 @default.
• W2034893607 hasIssue "12" @default.
• W2034893607 hasLocation W20348936071 @default.
• W2034893607 hasLocation W20348936072 @default.
• W2034893607 hasOpenAccess W2034893607 @default.
• W2034893607 hasPrimaryLocation W20348936071 @default.
• W2034893607 hasRelatedWork W1979645425 @default.
• W2034893607 hasRelatedWork W1989065679 @default.
• W2034893607 hasRelatedWork W2011514569 @default.
• W2034893607 hasRelatedWork W2041778023 @default.
• W2034893607 hasRelatedWork W2046291757 @default.
• W2034893607 hasRelatedWork W2070913528 @default.

• next